Join Growin Stock Community!

Kezar life sciences, inc.KZR.US Overview

US StockHealthcare
(No presentation for KZR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

KZR AI Insights

KZR Overall Performance

KZR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

KZR Recent Performance

1.19%

Kezar life sciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

KZR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

KZR Key Information

KZR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

KZR Profile

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

Price of KZR

KZR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

KZR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
  • When is KZR's latest earnings report released?

    The most recent financial report for Kezar life sciences, inc. (KZR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating KZR's short-term business performance and financial health. For the latest updates on KZR's earnings releases, visit this page regularly.

  • How much debt does KZR have?

    As of the end of the reporting period, Kezar life sciences, inc. (KZR) had total debt of 9.91M, with a debt ratio of 0.1. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does KZR have?

    At the end of the period, Kezar life sciences, inc. (KZR) held Total Cash and Cash Equivalents of 38.94M, accounting for 0.4 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is KZR's EPS continuing to grow?

    According to the past four quarterly reports, Kezar life sciences, inc. (KZR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.53. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of KZR?

    Kezar life sciences, inc. (KZR)'s Free Cash Flow (FCF) for the period is -9.82M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 43.92% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-8.43
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
6.03
PB Ratio
0.59
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-8.43
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
6.03
PB Ratio
0.59
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%